polycystic ovary syndrome affects 1 in 10 women of childbearing age. The exact cause of the condition is unknown; however, obesity, high levels of inflammation and insulin resistance are the common risk factors
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
- A detailed assessment of the therapeutic pipeline activity and therapeutic assessment of the products.
- Detailed profiles of the players that are engaged in the development of drug products / therapies for polycystic ovarian syndrome.
- An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III).
- A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs.
- An insightful analysis of the patents filed / granted for polycystic ovary syndrome, since 2016, taking into consideration various parameters.
- An in-depth analysis of grants awarded to various research institutes for the projects related to polycystic ovary syndrome, in the period between 2016 and April 2021.
- A detailed analysis of completed, ongoing and planned clinical studies, based on the various relevant parameters.
- A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
- Drug Class
- Insulin Sensitizing Agents
- Oral Contraceptives
- Route of Administration
- Regional Distribution
- North America (US, Canada)
- Europe (France, Germany, Italy, Spain, UK)
- Asia-Pacific and Rest of the World (Australia, China, India and Japan)
Key companies covered in the report
- Lupin Pharmaceuticals
- Teva Pharmaceuticals
For more information please click on the following link:
Other Recent Offerings
- Non-hormonal Therapies for Women’s Health Market, 2021-2030
- Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
- Vascular Disrupting Agents Market, 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at email@example.com
+1 (415) 800 3415
Facebook – https://www.facebook.com/RootsAnalysis